

Upcoming Medicaid Pharmacy Benefit Changes

Neighborhood News – July 2024

Effective **August 1, 2024**, Neighborhood Health Plan of Rhode Island's (Neighborhood) Medicaid Pharmacy Benefit will be making the following Formulary changes:

Saxenda

Saxenda will be removed from the Medicaid Formulary with Wegovy and Zepbound being the preferred alternative. Medicaid members utilizing Saxenda can remain on current treatment through the end of their current Authorization. A new prescription and Authorization will be required for Wegovy or Zepbound.

Invokamet and Invokamet XR

Invokamet and Invokamet XR will be removed from the Medicaid Formulary with generic dapagliflozin/metformin being the preferred alternatives. Medicaid members utilizing Invokamet or Invokamet XR can remain on current treatment through January 1, 2025.

Somatuline Depot

Somatuline Depot will be removed from the Medicaid Pharmacy Benefit Formulary and must be billed on Neighborhood's Medical Benefit.

Effective **October 1, 2024**, Neighborhood's Medicaid Pharmacy Benefit will be making the following Formulary change:

Basaglar and Semglee

Both medications will be removed from the Medicaid Formulary with Lantus, Rezvoglar, and insulin glargine-YFGN being the preferred alternatives. Medicaid members utilizing Basaglar or Semglee will need a new prescription for a preferred long-acting insulin product. A new prescription for Lantus, Rezvoglar, or insulin glargine-YFGN can be sent to the member's preferred pharmacy before **October 1, 2024**, to ensure a smooth transition.

Note: These changes do not affect Commercial or INTEGRITY members.